Fuda Cancer Hospital
Fuda Cancer Hospital
Chiny, Kanton
Liver cancer stage 3 treatment cost in China typically involves diagnostic imaging like CT of the chest, which runs $300 to $600, and specialized therapies. Primary treatments include chemotherapy for breast cancer costing $14,800 to $31,000 or radiation therapy for colorectal cancer ranging from $11,500 to $27,500. Total expenses depend on the hospital tier and drug origins. Patients often save 50-85% compared to US costs. Top treatment hubs include Guangzhou, Beijing, and Shanghai.
Typical Liver Cancer Stage 3 Treatment Costs in China
Bookimed Expert Insight: Advanced stage patients seeking alternatives to traditional chemotherapy should consider specialized centers like Fuda Cancer Hospital. This JCI-accredited facility specializes in minimally invasive therapies, including NanoKnife and cryosurgery. Dr. Liuying at Jinshazhou Hospital provides expert care in thermal ablation for hepatocellular carcinoma. These targeted approaches are best for patients requiring high-precision treatment while preserving healthy liver tissue.
| Chiny | Turcja | Austria | |
| Radioterapia raka odbytnicy | od $11,500 | od $7,000 | od $12,000 |
| Chemioterapia w raku piersi | od $14,800 | od $1,200 | od $15,000 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia raka wątroby 3 stopnia odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu raka wątroby 3 stopnia. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia raka wątroby 3 stopnia.
Dr. Liuying leads the Oncology Ward at Jinshazhou Hospital, Guangzhou University of Chinese Medicine. Clinical focus includes hepatocellular carcinoma, cholangiocarcinoma, and lung and colorectal cancers. Dr. Liuying has special expertise in melanoma and melanoma liver metastasis. Interventional skills include MWA, RFA, cryoablation, and radioactive seed implantation for non-vascular, minimally invasive tumor ablation.
Research: participated in two Guangdong Provincial science and technology projects. Contributed to the 2014 Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors. Published in the Chinese Journal of Lung Cancer. Compiled Selected Cases of Microwave Ablation for Lung Tumors and Selected Cases of Microwave Ablation for Liver Tumors.
Appointments: Standing Committee Member, Youth Committee of Intra-Tumor Brachytherapy Medicine, China Medical Education Association. Standing Committee Member, Minimally Invasive Interventional Medicine Professional Committee, Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
In the China Liver Cancer staging system, Stage 3 signifies advanced hepatocellular carcinoma. It is categorized into Stage 3a, involving major blood vessel invasion, and Stage 3b, indicating spread to distant organs. Chinese guidelines often favor aggressive surgical or combination treatments over purely palliative care.
Bookimed Expert Insight: Chinese oncology centers often apply aggressive local treatments for Stage 3 that differ from Western protocols. Dr. Liuying at Jinshazhou Hospital specializes in combining microwave ablation with radioactive seed implantation. This multi-step approach at JCI-accredited facilities like Fuda Cancer Hospital aims for significant results even in advanced stages.
Patient Consensus: Patients note that the label matters less than checking for portal vein invasion. They emphasize confirmed liver function quality often dictates how aggressively doctors will pursue surgery or ablation.
Chinese clinical guidelines are more aggressive than Western protocols for Stage 3 liver cancer. Surgery remains a primary option for patients with Stage 3a tumors involving portal vein invasion. Doctors also use conversion therapy to shrink Stage 3b tumors until they become surgically removable.
Bookimed Expert Insight: While Stage 3 is often considered terminal elsewhere, China’s high-volume centers focus on multidisciplinary downstaging. Fuda Cancer Hospital has treated over 30,000 international patients by specializing in late-stage oncology. Their use of minimally invasive vascular therapy often bridges the gap between unresectable and surgical status.
Patient Consensus: Patients emphasize that a second opinion from a liver specialist is vital for determining resectability. Many note that factors like cirrhosis and bilirubin levels matter more than the stage number itself.
China standardizes systemic combination therapies for Stage 3 liver cancer according to Chinese National Liver Cancer guidelines. Preferred first-line treatments combine immune checkpoint inhibitors with anti-angiogenic drugs. Doctors frequently integrate these with regional therapies like chemoembolization to manage tumor spread and vascular invasion.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital often prioritize multi-modal approaches earlier than Western protocols. While guidelines suggest systemic drugs, data shows specialists frequently add microwave hyperthermia or vascular interventional therapy. This aggressive local control reflects a high specialization in late-stage cases across 30,000+ international patients.
Patient Consensus: Patients note that doctors often adjust treatments quickly based on lab results. Many emphasize that managing side effects like fatigue from TACE is essential during recovery.
China utilizes domestic PD-1 inhibitors like Camrelizumab and Sintilimab alongside global drugs like Pembrolizumab and Nivolumab. For liver cancer, physicians frequently combine these with targeted therapies. Lenvatinib and Sorafenib remain the primary targeted options approved by the National Medical Products Administration.
Bookimed Expert Insight: While global centers often lead with single-agent or specific duo-therapies, Chinese oncology experts at facilities like Fuda Cancer Hospital emphasize multi-modal strategies. They frequently integrate these approved drugs with unique minimally invasive therapies like cryosurgery or NanoKnife. This approach aims to reduce the tumor burden physically while using systemic drugs to maintain response, particularly for stage 3 cases where surgery alone is insufficient. This aggressive combination of local and systemic treatment is a hallmark of high-volume Chinese cancer centers.
Patient Consensus: Patients note that domestic PD-1 drugs are often more affordable and accessible than imported brands. Many emphasize that doctors prioritize liver function and side effects like hand-foot syndrome when choosing between Lenvatinib or Sorafenib.
Hepatic arterial infusion chemotherapy (HAIC) delivers high-concentration chemotherapy directly into the liver tumor through an implanted catheter. China uses it frequently to treat advanced hepatocellular carcinoma. This approach maximizes tumor exposure while minimizing systemic side effects. It remains a standard for patients with large or complex tumors.
Bookimed Expert Insight: While many Western centers offer standard chemo, Chinese facilities like Fuda Cancer Hospital utilize vascular interventional therapy for over 30,000 international patients. Data shows success here often stems from combining HAIC with technologies like NanoKnife or cryosurgery. This multi-modality approach is specifically designed for tumors that are otherwise inoperable.
Patient Consensus: Patients note that HAIC is used as a bridge to shrink tumors before attempted surgery. Successful treatment depends heavily on the skill of the interventional radiologist managing the catheter.
China uses Traditional Chinese Medicine (TCM) as a supportive therapy for Stage 3 liver cancer. It complements surgery, chemotherapy, and radiation rather than replacing them. Specialists use TCM to manage treatment toxicity. This integration helps patients complete their conventional clinical cycles more comfortably.
Bookimed Expert Insight: Clinics like Fuda Cancer Hospital combine JCI-accredited standards with advanced minimally invasive therapies. Dr. Liuying at Jinshazhou Hospital specializes in microwave and radiofrequency ablation. This highlights a trend where Chinese oncology centers prioritize high-tech tumor destruction. They utilize TCM primarily as a baseline system to help the body tolerate aggressive interventions.
Patient Consensus: Patients note it is vital to use TCM only for managing side effects. They emphasize that relying on herbs alone for advanced cancer is risky and may delay necessary treatment.